ONCY Oncolytics Biotech
- 1.145
- -0.035-2.97%
Oncolytics Biotech News
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection
USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can ...
Oncolytics Biotech Joins GCAR for Cancer Trial
Oncolytics Biotech Enters Preliminary Collaboration With The Global Coalition For Adaptive Research
The purpose of the preliminary collaboration is to commence planning activities for the evaluation of pelareorep in the treatment of first-line metastatic pancreatic ductal adenocarcinoma (PDAC) as pa
Oncolytics Biotech Brief: Announcing Preliminary Collaboration With GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
07:01 AM EDT, 05/15/2024 (MT Newswires) -- Oncolytics Biotech Brief: Announcing Preliminary Collaboration with GCAR for Inclusion of Pelareorep in Anticipated Pancreatic Cancer Trial
HC Wainwright & Co. Reiterates Buy on Oncolytics Biotech, Maintains $5 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Oncolytics Biotech with a Buy and maintains $5 price target.
Oncolytics Biotech Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 316.91% HC Wainwright & Co. → $5 Reiterates Buy → Buy 04/04/2024 150.15% Raymond James → $3 Ini
Buy Rating Affirmed on Oncolytics Biotech's Advancements and Prospective Partnerships in Cancer Treatment Pipeline
RBC on Oncolytics Biotech's Upcoming Type C Meeting With FDA
A Type C meeting with the Food and Drug Administration in the coming few weeks will establish registrational pathway for Oncolytic Biotech's pelareorep in HR+/HER2- metastatic breast cancer, notes RBC
Analysts' Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Aveanna Healthcare Holdings (AVAH) and Sanofi (OtherSNYNF)
Analysts Are Bullish on These Healthcare Stocks: Oncolytics Biotech (ONCY), Lineage Therap (LCTX)
Earnings Call Summary | Oncolytics Biotech(ONCY.US) Q1 2024 Earnings Conference
The following is a summary of the Oncolytics Biotech, Inc. (ONCY) Q1 2024 Earnings Call Transcript:Financial Performance:Oncolytics Biotech reported a cash position of $29.6 million at the end of Q1 2
Oncolytics Biotech Posts Increased Q1 Loss
Oncolytics Biotech Eyes Key Clinical Milestones
6-K: Report of foreign private issuer (related to financial reporting)
Oncolytics Biotech Q1 EPS $(0.07) Beats $(0.08) Estimate
Oncolytics Biotech (NASDAQ:ONCY) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is unchanged from the same period last year.
Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million
Oncolytics Biotech (ONC.TO), which earlier Thursday reported it received German regulatory approval to start enrollment into a new GOBLET study pancreatic cancer cohort, said its first-quarter loss wi
Oncolytics Biotech 1Q R&D Expenses C$5.7M >ONC.T
Oncolytics Biotech 1Q R&D Expenses C$5.7M >ONC.T
Oncolytics Biotech Brief: Q1 Basic and Diluted Loss per Common Share $0.09
04:01 PM EDT, 05/09/2024 (MT Newswires) -- Oncolytics Biotech Brief: Q1 Basic and diluted loss per common share $0.09
Press Release: Oncolytics Biotech(R) Reports First Quarter 2024 Financial Results and Operational Highlights
Oncolytics Biotech(R) Reports First Quarter 2024 Financial Results and Operational Highlights PR Newswire SAN DIEGO and CALGARY, AB, May 9, 2024 Pelareorep advancing to registration-enabling studie
Fight Against Pancreatic Cancer Ramps Up as Market Size Revenues Expected to Exceed $36 Billion by 2036
The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society...
Analysis
Price Target
No Data
